Rosetta Genomics (ROSG) Ticks Higher as CUP Test Manuscript Accepted by JMC

Rosetta Genomics Ltd. (Nasdaq: ROSG) are up notably today following an earlier announcement that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test™ (formerly miRview mets2) to identify the tumor of origin in Cancer of Unknown or Uncertain Primary (CUP) has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article, titled "Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary," represents the seventh peer-reviewed publication relating to our CUP assays, and the fifth peer-reviewed publication relating to post market validation studies demonstrating the Cancer Origin Test's ability to identify tumor origin in CUP with 92% concordance, the highest level of accuracy of any similar study published to date.

The manuscript discusses the performance of the Cancer Origin Test, an assay utilizing 64 microRNAs to identify 42 tumor types, in formalin-fixed paraffin-embedded (FFPE) samples from 84 CUP patients The results showed concordance with the final diagnosis in 92% of patients; representing an improvement in agreement of 22 percentage points from presentation diagnosis to final diagnosis, which final diagnosis was achieved after more precise clinical and pathological data was added to the data relied upon for the patient's initial assessment.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Home Depot expands executive roles, grants $500K in restricted stock
• Kimbell Royalty closes $221.2M mineral rights acquisition